Sophiris Bio Inc. (SPHS) Stock Price Down 3.8%
Sophiris Bio Inc. (NASDAQ:SPHS) dropped 3.8% during trading on Wednesday . The stock traded as low as $3.65 and last traded at $3.85, with a volume of 2,526,601 shares traded. The stock had previously closed at $4.00.
Several research analysts recently issued reports on the stock. Maxim Group reiterated a “buy” rating and issued a $4.00 price target on shares of Sophiris Bio in a research note on Thursday, March 24th. Echelon Wealth Partners reiterated a “buy” rating and issued a $5.00 price target on shares of Sophiris Bio in a research note on Friday, June 10th.
The firm’s market capitalization is $95.34 million. The stock has a 50-day moving average of $2.16 and a 200 day moving average of $1.69.
Sophiris Bio (NASDAQ:SPHS) last posted its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.06. Equities research analysts anticipate that Sophiris Bio Inc. will post ($0.73) earnings per share for the current year.
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.